The Traderszone Network

Published in TZ Latest News 28 June, 2021 by The TZ Newswire Staff

Here’s Why Exelixis Stock Is Dropping Today

Shares of Exelixis (NASDAQ: EXEL), an oncology-focused biopharmaceutical company, started sliding Monday in response to a disappointing clinical trial readout. Investors responding to results that weren’t quite good enough have shaved 20.1% from the stock’s price as of 11:30 a.m. EDT. 

read more